Vaxart Faces Proxy Contest as Dissident Shareholder Nominates Rival Board Slate
VXRT has more than doubled off its 52-week low of $0.261.
Summary
Vaxart has filed its preliminary proxy statement, revealing a proxy contest initiated by a shareholder group seeking to replace board members at the upcoming 2026 Annual Meeting. The company's board is urging shareholders to vote for its recommended nominees and against the dissident slate.
Key Events · Corporate Governance and Compliance · VXRT
-
Proxy Contest Initiated
A shareholder group led by Daniel P. Houle has nominated three candidates for election to the Board of Directors at the 2026 Annual Meeting, opposing the company's recommended nominees.
-
Board Rejects Dissident Nominees
Vaxart's Board of Directors unanimously recommends voting 'FOR' its six proposed nominees and 'NOT' for the three candidates put forth by the Houle Group, citing their lack of relevant industry experience.
-
Shareholder Activism Continues
This proxy contest follows a history of shareholder opposition, including the failure to approve a reverse stock split in 2025, which led to the company's delisting from Nasdaq.
-
Dissident Group Holdings
The Houle Group collectively owned approximately 0.7% of Vaxart's outstanding common stock as of February 20, 2026.
Analysis · VXRT · Life Sciences
This preliminary proxy statement formally details Vaxart's position in a significant proxy contest. A dissident shareholder group, led by Daniel P. Houle, is challenging the current board by nominating three alternative candidates for election. The Board has unanimously rejected these nominees, citing a lack of relevant industry experience, and is actively urging shareholders to vote for its own slate. This event is particularly critical given Vaxart's recent history of shareholder activism, including the failure to pass a reverse stock split in 2025 which resulted in Nasdaq delisting. The outcome of this contest could lead to substantial changes in corporate governance and potentially influence the company's strategic direction, especially following its recent financial turnaround and alleviation of its going concern warning.
At the time of this filing, VXRT was trading at $0.61 on OTC in the Life Sciences sector, with a market capitalization of approximately $147.6M. The 52-week trading range was $0.26 to $0.84. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.